IL-6在卵巢癌患者体内的高频率检出及其临床意义分析的初步观察

High Identification Rate and Significance of Interleukin 6 in Sera and Peritoneal Fluids of Ovarian Cancer Patients

利用IL－6生存依赖性小鼠杂交后7TD1细胞对卵巢癌细胞培养上清液和卵巢肿瘤患者的血清和腹水样本进行了IL－6的生物活性测定，结果显示：体外培养的2株卵巢癌细胞系都有自发产生IL－6的能力，在良性病变的18例血清和6例腹腔渗出液中，IL－6检出率仅为11．1％和16．7％，相反，12例卵巢癌血清和14例恶性腹水样本分别达75％和100％，11例癌瘤术后化疗的血清样本中，7例IL－6阴性，4例阳性（36．4％）。结果提示，外周血IL－6的水平与卵巢肿瘤的恶性转化明显相关，故可望成为卵巢肿瘤鉴别诊断和抗癌疗效监测的新的生物指标。

In this study, IL-6 levels in sera and peritoneal fluids of patients with benign or malignant ovarian tumors were determined at bioassay using IL-6 dependent murine B-cell hybridoma 7TD1 cell line. It was found that IL-6 discovery rates were 11.1% and 16.7% in the sera and peritoneal fluid of patients bearing benign tumor ;however, in cancer patients disregarding stage Ⅰor Ⅱ these rates reached 75% and100%. The quantitative difference of IL-6 level in sera and peritoneal fluid were also demonstrated between the benign and malignant ovarian tumors. It was also found thatthe concentration of IL-6 in peripheral blood closely correlated with malignancy of theovarian tumors. Our study thus indicate that IL-6 level in serum or peritoneal fluidmight be a useful biomarker in the diagnosis and assessment of prognosis in patientswith ovarian cancer.